223 related articles for article (PubMed ID: 35186171)
21. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
Fujimura T; Aiba S
Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
[TBL] [Abstract][Full Text] [Related]
22. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
Preston CC; Maurer MJ; Oberg AL; Visscher DW; Kalli KR; Hartmann LC; Goode EL; Knutson KL
PLoS One; 2013; 8(11):e80063. PubMed ID: 24244610
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
25. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.
Peng Y; Wang H; Huang Q; Wu J; Zhang M
J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063
[TBL] [Abstract][Full Text] [Related]
26. CAPG enhances breast cancer metastasis by competing with PRMT5 to modulate STC-1 transcription.
Huang S; Chi Y; Qin Y; Wang Z; Xiu B; Su Y; Guo R; Guo L; Sun H; Zeng C; Zhou S; Hu X; Liu S; Shao Z; Wu Z; Jin W; Wu J
Theranostics; 2018; 8(9):2549-2564. PubMed ID: 29721098
[TBL] [Abstract][Full Text] [Related]
27. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.
Ko SY; Ladanyi A; Lengyel E; Naora H
Am J Pathol; 2014 Jan; 184(1):271-81. PubMed ID: 24332016
[TBL] [Abstract][Full Text] [Related]
28. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
29. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer.
Zhu WY; Hunag YY; Liu XG; He JY; Chen DD; Zeng F; Zhou JH; Zhang YK
Anat Rec (Hoboken); 2012 Feb; 295(2):208-14. PubMed ID: 22190510
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and clinicopathological significance of CapG in various cancers: Evidence from a meta-analysis.
Lang Z; Chen Y; Zhu H; Sun Y; Zhang H; Huang J; Zou Z
Pathol Res Pract; 2019 Dec; 215(12):152683. PubMed ID: 31685300
[TBL] [Abstract][Full Text] [Related]
31. Comparisons of CapG and gelsolin-null macrophages: demonstration of a unique role for CapG in receptor-mediated ruffling, phagocytosis, and vesicle rocketing.
Witke W; Li W; Kwiatkowski DJ; Southwick FS
J Cell Biol; 2001 Aug; 154(4):775-84. PubMed ID: 11514591
[TBL] [Abstract][Full Text] [Related]
32. DCK is a promising prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.
Song D; Wang Y; Zhu K; Tian L; Gao Q; Zhou J; Fan J; Wang X
World J Surg Oncol; 2020 Jul; 18(1):176. PubMed ID: 32690026
[TBL] [Abstract][Full Text] [Related]
33. CD4
Liu S; Tao Z; Lou J; Li R; Fu X; Xu J; Wang T; Zhang L; Shang W; Mao Y; Wang F
J Transl Med; 2023 Nov; 21(1):803. PubMed ID: 37950246
[TBL] [Abstract][Full Text] [Related]
34. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
35. CMA1 is potent prognostic marker and associates with immune infiltration in gastric cancer.
Shi S; Ye S; Mao J; Ru Y; Lu Y; Wu X; Xu M; Zhu T; Wang Y; Chen Y; Tang X; Xi Y
Autoimmunity; 2020 Jun; 53(4):210-217. PubMed ID: 32129682
[No Abstract] [Full Text] [Related]
36. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
[TBL] [Abstract][Full Text] [Related]
37. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic potential of macrophage‑capping protein in clear cell renal cell carcinoma.
Chen ZF; Huang ZH; Chen SJ; Jiang YD; Qin ZK; Zheng SB; Chen T
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236143
[TBL] [Abstract][Full Text] [Related]
39. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
40. SEMA6B Overexpression Predicts Poor Prognosis and Correlates With the Tumor Immunosuppressive Microenvironment in Colorectal Cancer.
Li T; Yan Z; Wang W; Zhang R; Gan W; Lv S; Zeng Z; Hou Y; Yang M
Front Mol Biosci; 2021; 8():687319. PubMed ID: 34938771
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]